Sign In
Buy MEDP
$458.69
+7.88 (+1.75%)
At Close: Jun 04, 2026
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
07:15pm, Tuesday, 04'th Mar 2025
Medpace (MEDP) concluded the recent trading session at $324.13, signifying a +1.55% move from its prior day's close.
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Hold
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
11:00am, Saturday, 01'st Mar 2025
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Hold
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
10:00am, Thursday, 27'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
10:00am, Tuesday, 25'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
10:00am, Sunday, 23'rd Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
11:00am, Friday, 21'st Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
11:00am, Wednesday, 19'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
11:00am, Monday, 17'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace
